Fig. 1.

scRNA-seq reveals transcriptomic heterogeneity in MCL patients with diverse clinical outcomes. A Experimental design summarizing patient sample information. Patient samples were categorized into five clinical outcomes according to their sensitivity to BTKi or CAR-T therapy. The number of patients (n) were denoted in the plot. B UMAP visualization represents cells colored by cell type. C Dot plot illustrates marker gene expression across cell types. Colors indicate low (purple) to high (yellow) expression. The circle size is proportional to the percentage of cells in which the gene was expressed. D UMAP visualization represents cells colored by clinical outcomes. E Bar plot shows cell type frequencies (x-axis) of each sample (y-axis) in the BTKi (left) or CAR-T (right) cohorts. Dot in front of each sample indicate clinical outcomes